Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665639 | 1.00 | ESR1 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| Bromide SCHEMBL10357246 | 0.98 | ESR1 (0.54) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL20683073 | 0.95 | ESR1 (0.58) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL32665589 | 0.89 | DRD2 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL1370024 | 0.87 | DRD2 (0.53) | ESR1ESR2DRD2DRD3OPRK1 | |
| Acetic Acid SCHEMBL20533151 | 0.86 | ESR1 (0.50) | ESR1ESR2DRD2DRD3OPRK1 | |
| Acetic Acid SCHEMBL20533149 | 0.86 | ESR1 (0.50) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL2803692 | 0.85 | ACHE (0.51) | ESR1ESR2DRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL2807478 | 0.84 | ACHE (0.50) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL22652225 | 0.81 | KDM1A (0.45) | ESR1ESR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-0253257-A2 | Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, method for their preparation and their application as medicaments | BAYER AG (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ESR1 3027/4885ESR2 2648/4885DRD2 3348/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | ESR1 3027/4885ESR2 2648/4885DRD2 3348/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | ESR1 3027/4885ESR2 2648/4885DRD2 3348/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | ESR1 3453/4885ESR2 941/4885DRD2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.